07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

EpiFix: Clinical trial data

An open-label, U.S. clinical trial in 60 patients with diabetic foot ulcers showed that weekly applications of EpiFix led to complete wound healing in 85% of patients at week 4 vs. 35% of patients receiving...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

EpiFix regulatory update

MiMedx said a Medicare contractor responsible for about 5 million beneficiaries in Texas, Oklahoma, Louisiana, New Mexico, Colorado, Mississippi and Arkansas revised its local coverage determination for bioengineered skin substitutes in the hospital outpatient and...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

EpiFix regulatory update

MiMedx said it received reimbursement coverage from Medicare contractor First Coast Service Options Inc. for the company's EpiFix wound care allograft in the hospital outpatient and ambulatory surgery center settings. The company said EpiFix now...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

EpiFix amniotic membrane allograft regulatory update

On Dec. 12, 2013, MiMedx said it received reimbursement coverage from Medicare contractor CGS Administrators LLC for the company's EpiFix wound care allograft for diabetic foot ulcers and venous leg ulcers that fail to respond...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

MiMedx Group, Systagenix sales and marketing update

Systagenix launched Epifix in the U.S. to treat acute and chronic wounds. Systagenix has rights to the human amniotic allograft under a 2012 deal with MiMedx Group. Epifix is produced by MiMedx' Surgical Biologics company....